Director
Gastroenterology
Dr. Mitchell L. Shiffman, MD
|
|
Give Review
Doctor Mitchell L. Shiffman, MD works in the field of Gastroenterology. He graduated from State University of New York Upstate Medical University. He has 2 awards "America's Top Doctors" and "CMS Meaningful Use Stage 1 Certification". Mitchell Shiffman is also a published physician. He has 98 publication published. The most recent publication is: Safety and Efficacy of Ledipasvir-Sofosbuvir in African Americans with Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data. He is registered with Medicare and accepts Medicare payments.
Publications
- Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
- Safety and Efficacy of Ledipasvir-Sofosbuvir in African Americans with Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data.
- Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon and/or Ribavirin.
- Cure of HCV related Liver disease.
- My Treatment Approach to Chronic Hepatitis C Virus.
- The role of interferon in the new era of Hepatitis C treatments.
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis.
- ABT-450/r-ombitasvir and dasabuvir with ribavirin for Hepatitis C with cirrhosis.
- Hepatitis C virus therapy in the direct acting antiviral era.
- Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study.
- All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV Infection.
- HCV F1/F2 patients: treat now or continue to wait.
- DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon Alpha-2a/ribavirin in HCV genotypes 1 or 4.
- Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients with HCV Infection and Cirrhosis, Allowing for Effective AntiViral Therapy.
- A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of Hepatitis C after liver transplantation.
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options.
- Intensified peginterferon ?-2a dosing increases sustained virologic response rates in heavy, high viral load Hepatitis C genotype 1 patients with high low-density lipo...
- Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
- Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation.
- Retreatment with telaprevir combination therapy in Hepatitis C patients with well-characterized prior treatment response.
- Interferon-free regimens: the near future, the likely and the not so likely.
- Genome-wide association study of interferon-related cytopenia in chronic Hepatitis C patients.
- Mild alcohol consumption is not associated with increased fibrosis in patients with chronic Hepatitis C.
- Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic Hepatitis B.
- Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired Liver biopsy samples.
- Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic Hepatitis C virus infection.
- A sustained virologic response is durable in patients with chronic Hepatitis C treated with peginterferon alfa-2a and ribavirin.
- Efficacy and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Renal Impairment.
- Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic Hepatitis C.
- Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 Hepatitis C virus infection.
- Histologic evidence of active liver injury in chronic Hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels.
- Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 Hepatitis C virus.
- Identifying Hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin.
- Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in Hepatitis C patients with advanced fibrosis and cirrhosis.
- Management of acute Hepatitis B.
- Treatment of Hepatitis C in 2011: what can we expect?
- Herpes simplex virus colitis in a patient with Crohn's disease and Hepatitis B and d cirrhosis.
- Response to Hepatitis A and B vaccine alone or in combination in patients with chronic Hepatitis C virus and advanced fibrosis.
- A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic Hepatitis C: ViSER1 results.
- Retreating chronic Hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
- Incidence of prolonged length of stay after orthotopic Liver transplantation and its influence on outcomes.
- Impact of the donor liver with steatosis in patients with Hepatitis C virus: not so FAst.
- Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic Hepatitis B.
- Prolonged therapy of advanced chronic Hepatitis C with low-dose peginterferon.
- Sustained Hepatitis B e antigen seroconversion in patients with chronic Hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mut...
- Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of Chronic hepati...
- High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
- A single center review of the use of mycophenolate mofetil in the treatment of Autoimmune hepatitis.
- R1626 plus peginterferon Alfa-2a provides potent suppression of Hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
- Optimizing the current therapy for chronic Hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors.
- Role and support for hepatologists at Liver transplant programs in the United States.
- Steatohepatitis: Risk factors and impact on disease severity in human immunoDeficiency virus/hepatitis C virus coinfection.
- Surveillance for hepatocellular carcinoma in patients with Cirrhosis improves outcome.
- The impact of fat distribution on the severity of nonalcoholic Fatty liver disease and metabolic syndrome.
- A balancing view: We cannot do it alone.
- A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic Hepatitis C.
- Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin Alpha.
- Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of Hepatitis C virus.
- Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic Hepatitis C.
- Treating chronic Hepatitis C virus after liver transplantation: balancing the risks against the chance for success.
- A prospective evaluation of fibrosis progression in patients with recurrent Hepatitis C virus following liver transplantation.
- Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival.
- Treatment of chronic Hepatitis C virus in African Americans with genotypes 2 and 3.
- Strategies for managing Anemia in hepatitis C patients undergoing antiviral therapy.
- Impact of ribavirin dose reductions in Hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
- Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic Hepatitis C.
- Use of ribavirin in patients with Chronic HCV genotype 1: when enough is really enough.
- Chronic Hepatitis C in patients with persistently normal alanine transaminase levels.
- Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic Hepatitis C.
- Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatoHepatitis and Hepatitis C.
- Approach to the management of patients with chronic Hepatitis C who failed to achieve sustained virologic response.
- Chronic Hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.
- Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic Hepatitis C.
- The spectrum of chronic Hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV.
- A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatoHepatitis.
- Histologic recurrence of chronic Hepatitis C virus in patients after living donor and deceased donor liver transplantation.
- Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent Hepatitis C following liver transplantation.
- Hepatitis C with normal liver enzymes: to treat or not to treat. A balancing view: a decision to be shared with patients.
- A comparison of the spectrum of chronic Hepatitis C virus between Caucasians and African Americans.
- Impact of highly Active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection.
- Treatment of chronic Hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?
- Retreatment of patients who do not respond to initial therapy for chronic Hepatitis C.
- Controversies in the management of Hepatitis C patients with advanced fibrosis and cirrhosis.
- Management of patients with chronic Hepatitis C virus infection and previous nonresponse.
- Use of diagnostic testing for managing Hepatitis C virus infection.
- Controversies in the management of Hepatitis C virus infection after liver transplantation.
- Natural history and risk factors for progression of Hepatitis C virus disease and development of hepatocellular cancer before liver transplantation.
- Living donor liver transplantation in patients with chronic Hepatitis C: timing is everything.
- Nonalcoholic fatty liver disease in patients with Hepatitis C is associated with features of the metabolic syndrome.
- Clinical and histologic spectrum of nonalcoholic Fatty liver disease associated with normal ALT values.
- Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic Hepatitis C v...
- A survey of Liver transplantation from living adult donors in the United States.
- The clinical spectrum of Hepatitis C virus in HIV coinfection.
- Intensive interferon therapy does not increase virological response rates in African Americans with chronic Hepatitis C.
- Retreatment of patients with chronic Hepatitis C.
- Peginterferon alfa-2a plus ribavirin for chronic Hepatitis C virus infection.
- Living donor Liver transplantation: summary of a conference at The National Institutes of Health.
Schools
SUNY Upstate Medical University Syracuse
Med College Va
Procedures Preformed
- Liver Biopsy
- Liver Test
Conditions Treated
- Abdominal Pain
- Alpha 1-Antitrypsin Deficiency
- Anemia
- Autoimmune Hepatitis
- View All
Doctors Specialties
- Gastroenterology
- Hepatology
Accepted Insurances
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
Education
-
Virginia Commonwealth University Health System -
State University of New York Upstate Medical University
Drug Facts
| NPI NUMBER | 1497847461 | |
| NPPES Provider LastName | SHIFFMAN | |
| NPPES Provider FirstName | MITCHELL | |
| NPPES Provider ZIPCode | 236024414 | |
| NPPES Provider State | VA | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 504.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497847461 |
| Last Name Of The Provider | SHIFFMAN |
| First Name Of The Provider | MITCHELL |
| View All |
Similar Doctors
|
Dr. Frederick M. Gessner, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark A. Titus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth A. Adams, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa Odabasi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher W. Marshall, MD |
|
|
Dr. Keith A. Leibowitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ray L. James Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John R. Stephens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ashutosh S. Naniwadekar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John W. Boyd, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohamed B. El Safadi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gursharn S. Rakhra, MD
This Doctor is OpenDoctor Recommended.
|